Algernon Pharmaceuticals Inc AGNPF

Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > AGN.c starting to stabilize in the high $2 range.

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Nov 21, 2022 6:44pm

125 Views

Post# 35117058

AGN.c starting to stabilize in the high $2 range.

https://twitter.com/StckMasterFlash/status/1592966259284799488

As we have seen in the past they're price can jump quickly with the float being so tight with only 2.36M shares this tends to move following most updates.

AGN.c has begun screening subjects for their phase 1 DMT trials. Multiple DMT studies have been conducted so AGN.c expects a smooth and safe transition into phase 2.

<< Previous

Bullboard Posts

Next >>

Amazon stock reaches for record highs after earnings report